MedTrace Logo

Efficacy Study of Vx001 Vaccine in NSCLC Patients

NCT01935154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2019-06-19

No results posted yet for this study

Summary

Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A\*0201 positive patients with TERT expressing tumors will be included.

The objective of the trial is survival rate at 12 months.

Conditions

  • Non-small Cell Lung Cancer Metastatic

Interventions

DRUG

Vx-001

DRUG

Placebo

Sponsors & Collaborators

  • Vaxon Biotech

    lead INDUSTRY

Principal Investigators

  • Vassilis Georgoulias, MD,PhD · Iaso General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Poland
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935154 on ClinicalTrials.gov